Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 inhibitor plus apatinib with or without chemotherapy as maintenance in advanced driver gene-negative NSCLC
ChiCTR2600116429Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2026
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of Rivoceranib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600116429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116429.